Loading clinical trials...
Loading clinical trials...
Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults.
Conditions
Interventions
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
+2 more
Locations
7
United States
Alabaster, Alabama, United States
Sacramento, California, United States
Jacksonville, Florida, United States
Silver Spring, Maryland, United States
Springfield, Missouri, United States
Las Vegas, Nevada, United States
Start Date
December 6, 2011
Primary Completion Date
September 27, 2013
Completion Date
September 27, 2013
Last Updated
March 24, 2022
NCT04486638
NCT07007585
NCT06665035
NCT07040202
NCT06388785
NCT04619823
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions